2018•Hematology Transfusion and Cell TherapyOpen access
Philadelphia-negative myeloproliferative neoplasms as disorders marked by cytokine modulation
Maira da Costa Cacemiro, Juçara Gastaldi Cominal, Raquel Tognon, Natália de Souza Nunes, Belinda Pinto Simões, Lorena Lobo de Figueiredo‐Pontes, Luiz Fernando Bazzo Catto, Fabı́ola Traina, Elizabeth Xisto Souto, Fabiana Albani Zambuzi, Fabiani Gai Frantz, Fabíola Attié de Castro
Open full text 54 citations
Abstract
BACKGROUND: Cytokines are key immune mediators in physiological and disease processes, whose increased levels have been associated with the physiopathology of hematopoietic malignancies, such as myeloproliferative neoplasms. METHODS: This study examined the plasma cytokine profiles of patients with essential thrombocythemia, primary myelofibrosis, polycythemia vera and of healthy subjects, and analyzed correlations with JAK2 V617F status and clinical-hematological parameters. RESULTS: The proinflammatory cytokine levels were increased in myeloproliferative neoplasm patients, and the presence of the JAK2 V617F mutation was associated with high IP-10 levels in primary myelofibrosis patients. CONCLUSIONS: Essential thrombocythemia, primary myelofibrosis, and polycythemia vera patients exhibited different patterns of cytokine production, as revealed by cytokine network correlations. Together, these findings suggest that augmented cytokine levels are associated with the physiopathology of myeloproliferative neoplasms.